Table 1 Patient characteristics prior to the start of the study drug
From: Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial
Argatroban (number = 34) | Lepirudin (number = 32) | |
|---|---|---|
Age (years) | 68 ± 12 | 64 ± 17 |
Male (number) | 24 (71%) | 19 (59%) |
Body mass index (kg/m2) | 29 ± 9 | 26 ± 5 |
Simplified Acute Physiology Score II | 35 ± 14 | 36 ± 14 |
SOFA score | 10 ± 6 | 10 ± 4 |
Thromboembolic events (number) | 11 (32%) | 12 (38%) |
Hemoglobin (g/dl) | 10.1 ± 1.2 | 9.7 ± 1.0 |
Thrombocytes (per nl) | 144 ± 124 | 152 ± 160 |
INR | 1.2 ± 0.2 | 1.2 ± 0.3 |
aPTT (seconds) | 46.1 ± 8.6 | 43.9 ± 7.9 |
Thrombin time (seconds) | 27.7. ±29.2 | 19.0 ± 5.3 |
Duration of previous heparin therapy (days) | 16 ± 4 | 14 ± 12 |
Probability of HIT according to 4 T Score (number) | 0/22/12a | 3/23/6a |
(low /intermediate/high) | (0/65/35%) | (9/72/19%) |
General and visceral surgery (number) | 10 | 7 |
Vascular surgery (number) | 4 | 2 |
Cardiac surgery (number) | 19 | 18 |
Others (number) | 1 | 5 |
Chronic renal insufficiency (number) | 6 | 7 |